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Background: The relationship between alterations in thyroid function and cognitive deficits has been investigated
in several previous studies. Hypo-or hyperthyroidism and, to a lesser extent, subclinical thyroid dysfunction can
negatively affect cognitive performance. However, limited data are available on the potential association of thyroid
function with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) in the elderly Chinese population.
Methods: In the present study focusing on a population of elderly Chinese individuals ≥ 50 years of age, 77
cognitively normal controls, 64 patients with MCI, and 154 patients diagnosed with AD underwent assessment of
thyroid status using thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine (fT4) levels as
variables. Cognitive function was evaluated with the aid of comprehensive neuropsychological tests, such as the
Mini-Mental State Examination (MMSE) and Memory and Executive Screening (MES).
Results: Overall, 88.1 % of the subjects displayed normal thyroid function, 4.7 % were diagnosed with clinical
hypothyroidism, 3.1 % with subclinical hypothyroidism, and 4.1 % with subclinical hyperthyroidism. After adjusting
for covariates (age, sex, education years and body mass index), no association was evident between mild cognitive
impairment or AD and thyroid dysfunction. However, lower serum TSH was correlated with risk of AD (odds ratio
[OR]: 2.78, 95 % confidence interval [95% CI]: 1.11-6.99).
Conclusion: Neither hypothyroidism nor subclinical hyperthyroidism was associated with AD and MCI in this
population-based elderly Chinese cohort. Our findings need to be confirmed in a longitudinal study.
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Accumulating evidence has demonstrated that alter-
ations in interrelated endocrine axes are associated with
risk of cognitive decline [1]. Thyroid dysfunction may be
accentuated or accelerated in elderly people who develop
dementia [2]. Consequently, screening for thyroid dis-
ease is recommended in dementia workup [3], and the
serum thyroid stimulating hormone (TSH) level remains
a standard screening tool for the routine assessment of
patients presenting with cognitive impairment [3]. In
mild cognitive impairment (MCI) and Alzheimer’s dis-
ease (AD), subclinical thyroid disease and variations of
serum TSH within the reference interval have been* Correspondence: huyaodolphin@sina.cn
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development of the disease [4–6].
Earlier, the group of van Osch reported that lower
TSH is associated with AD [7]. Kalmijn et al. [8] add-
itionally showed that deviation in thyroid hormone levels
is a possible risk factor for AD. However, according to
previous population-based studies, baseline TSH is not
associated with changes over time in cognitive test per-
formance [2, 9, 10], although conflicting results have
been obtained on its association with risk of AD [8, 11–13].
Insufficient data are available regarding the relationship be-
tween clinical or subclinical thyroid disease and risk of
MCI development [14, 15]. Elucidation of thyroid hormone
interrelationships in MCI should provide opportunities for
earlier intervention in dementia.
The main objective of the current study was to investi-
gate thyroid hormone levels in patients with MCI andistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tential association with cognitive function with the aid
of comprehensive neuropsychological tests, such as
Mini-Mental State Examination (MMSE) and Memory
and Executive Screening (MES).
Methods
Subjects
A total of 295 participants were recruited, including 77
cognitively normal controls, 64 patients with MCI, and
154 patients with AD. Although normal control subjects
were not matched with patients in terms of age and gen-
der, the groups were not statistically different.
Individuals selected for cluster sampling in the
Jingansi Community, Shanghai, China, from January
2009 to June 2009 were enrolled as the normal
control group using the following inclusion criteria:
age range from 50 to 90 years, cognitively normal
based on the absence of significant impairment in
cognitive functions or activities of daily living (ADL),
no memory complaints or difficulties (verified by an
informant), Clinical Dementia Rating (CDR) = 0 [16],
Hamilton Depression Rating Score [17] less than or equal
to 12 on the 17-item scale in the preceding two weeks,
and adequate visual and auditory acuity to allow cognitive
testing. Exclusion criteria included a history of overt
thyroid disease, significant uncontrolled cardiac disease or
respiratory failure, insulin-dependent diabetes, uncor-
rected adrenal cortical insufficiency, chronic liver or renal
failure, malignant tumors, cerebrovascular accident, head
injury, other neurologic and psychiatric disorders/psych-
otic features with significant associated cognitive dysfunc-
tion, current antipsychotic or anxiolytic medication and
other treatments that may have altered thyroid hormone
levels, delirium, and recent history of alcohol abuse at the
time of assessment. This comparative cohort is an exten-
sion of the sample investigated by Guo et al. [18].
In total, 218 patients 50 to 90 years of age were re-
cruited from the Memory Clinic, Huashan Hospital of
Fudan University, between October 2010 and 2013. Pa-
tients underwent laboratory screening and cranial com-
puted tomography/magnetic resonance imaging scan,
with no clinically significant abnormalities in vitamin
B12, folic acid, rapid plasma reagin or treponema palli-
dum particle agglutination.
According to the Peterson criteria [19], MCI is defined
in cases of (a) memory complaints and difficulties, as
verified by an informant, (b) symptoms lasting more
than three months, (c) total score of the Mini Mental
State Examination-Chinese version (CMMSE) [20] ≥ cut-
off score adjusted for education, objective memory
impairment documented based on scoring below the
age- and education-adjusted cutoff values in tests of epi-
sodic memory, including the Auditory Verbal LearningTest [21], preserved basic activities of daily living
(ADL)/minimal impairment in complex instrumental
functions, (d) unknown etiology, (e) normal sense of
hearing and sight, (f ) not meeting diagnostic criteria of
dementia based on the National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) [22].
Probable AD was diagnosed according to the criteria
of NINCDS-ADRDA, CDR = 1, onset age ≥ 50 years, no
obvious medical, neurological or psychiatric disease or
psychological dysfunction, including anxiety and depres-
sion, within the previous one month, and no visual or
auditory deficits.
Thyroid hormone measurement and evaluation of thyroid
dysfunction
Fasting samples were collected from participants using
standard precautions. Serum fT3, fT4 and TSH levels
were measured via the chemiluminescent immunoassay
performed on an automated assay system (ADVIA Cen-
taur XP, Siemens, Germen). The interassay coefficients
of variation (CV %) for fT3, fT4 and TSH were 3.0, 4.0
and 6.4 (level one) and 2.5, 6.0 and 7.1 (level three), re-
spectively. All analyses were conducted using standard-
ized laboratory procedures.
Thyroid dysfunction was assessed based on measure-
ments of fT3, fT4 and TSH levels. According to our
laboratory-verified reference ranges, normal serum TSH,
fT3 and fT4 intervals were 0.55–4.78 mIU/l, 3.50–6.50
pmol/l and 11.50–22.70 pmol/l, respectively. Cut-off
levels for TSH were <0.55 mIU/l for hyperthyroidism
and >4.78 mIU/l for hypothyroidism. Cut-off levels for
fT4 and fT3 were <11.50 and <3.50 pmol/l for
hypothyroidism and >22.70 and >6.50 pmol/l for hyper-
thyroidism, respectively. Based on hormone levels, pa-
tients were classified into four categories: subclinical
hyperthyroidism (low serum TSH with normal fT3 and
fT4 levels), euthyroidism (normal TSH, fT3 and fT4),
subclinical hypothyroidism (high TSH with normal fT3
and fT4) and clinical hypothyroidism (high TSH com-
bined with low fT3 and/or fT4 levels).
Neuropsychological assessment
All participants were given neuropsychological tests by a
certificated professional who was unaware of the cause
or diagnosis. A comprehensive neuropsychological bat-
tery incorporating memory, language, attention, execu-
tive function and visuospatial ability was used, including
the Boston Naming Test (BNT) [23], Animal Verbal Flu-
ency Test (VFT) [24], Trail making Test (TMT) [25],
Stroop Color Word Test (CWT) [26], Clock-drawing
test (CDT) [27], clinical dementia rating scale (CDR)
[28], activity of daily living (ADL) [29] and Hamilton
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proven to have good reliability and validity in subjects
from a Chinese cultural background.
Assessment of cognitive function
Cognitive impairment was assessed by means of
CMMSE and MES [18]. MMSE is the most widely ap-
plied screening tool of mental function in the elderly,
routinely used as an outcome measure in clinical trials.
The test covers a range of cognitive domains, including
orientation to time and place, immediate memory and
recall, visuospatial ability, and language. For details on
MES, see Additional file 1. There are three indicators of
cognition. One sentence with ten main points is remem-
bered three times and free delay recalled twice. The
summation of five recall scores is MES-5R, which re-
flects instant and delayed memory and learning ability.
The four subtests of MES-EX include category fluency
test, sequential movement tasks, conflicting instructions
task and Go/No-go task. This reflects executive function.
The total potential score is100, with 50 each for MES-
5R and MES-EX. The neuropsychological status of each
participant was initially evaluated by a trained rater who
was blinded to the thyroid status of all subjects.
Statistical analysis
Means and standard deviation (SD) were calculated for
continuous variables, and significance differences evalu-
ated using one-way analysis of variance (ANOVA) in the
three groups (MCI, AD and normal control). Descriptive
characteristics of categorical variables were summarized
as frequencies, and comparisons among the three groups




Age, years (mean ± SD) 64.1 ± 10.4
Gender, No. (%)
Male 41 (53.2 %)
Female 36 (46.8 %)
BMI, kg/m2(mean ± SD) 23.8 ± 3.1
MMSE Score (mean ± SD) 28.0 ± 1.4
MES Score (mean ± SD) 84.0 ± 6.2
Education, years (mean ± SD) 10.1 ± 3.5
fT3, pmol/L (mean ± SD) 4.4 ± 0.5
fT4, pmol/L (mean ± SD) 15.2 ± 2.2
TSH, mU/L (mean ± SD) 2.0 ± 1.0
NC normal control, BMI body mass index
acompared with normal control after Bonferroni correction, MCI vs NC P < 0.001; AD
bcompared with normal control after Bonferroni correction, MCI vs NC P < 0.001; AD
cMCI vs NC P = 0.310; AD vs NC P = 0.011; AD vs MCI P = 0.220serum TSH, all participants were divided into five
groups, and logistic regression analyses performed using
the fifth quintile as the reference. Logistic regression was
used to evaluate the association of thyroid dysfunction
with MCI and AD (crude analysis and multivariate
adjustment for age, sex and body mass index). All
calculated P values were unpaired and two-tailed, and
differences considered statistically significant at P < 0.05.
Bonferroni correction was applied to adjust for multiple
comparisons. Data were analyzed using the Statistical
Package for Social Sciences (SPSS 13.0, SPSS Inc., USA).
Ethics statement
Our study was approved by the Huashan Hospital
Foundation Ethical Committee. Written informed consent
was obtained from all participants. All clinical investigations
were conducted according to the principles expressed in
the Declaration of Helsinki.
Results
Study population
Data from 295 eligible participants were analyzed. The
demographic characteristics, neuropsychological assess-
ments and thyroid status of normal control, MCI and
AD patients at baseline are presented in Table 1. The
mean ages of patients in the normal control, MCI and
AD groups were 64.1, 64.3 and 63.5 years, respectively.
We observed no significant differences in six demo-
graphic variables (age, gender, body mass index, years of
education, fT4 and TSH) among the three groups. The
means of two variables among the three groups, i.e.,
MMES and MES scores, were significantly different (P <
0.017) after Bonferroni correction. In terms of fT3, weDisease status P value
MCI AD
(n = 64) (n = 154)
64.3 ± 9.6 63.5 ± 9.4 0.822
0.091
35 (54.7 %) 86 (55.8 %)
29 (45.3 %) 68 (44.2 %)
23.4 ± 3.2 23.4 ± 3.1 0.081
26.1 ± 1.8 14.9 ± 5.9 <0.017a
63.4 ± 10.9 32.8 ± 18.9 <0.017b
9.4 ± 3.5 8.9 ± 4.2 0.094
4.5 ± 0.6 4.6 ± 0.5 0.032c
15.0 ± 1.8 14.8 ± 2.1 0.295
2.0 ± 1.5 1.8 ± 1.4 0.359
vs NC P < 0.001; AD vs MCI P < 0.001
vs NC P < 0.001; AD vs MCI P < 0.001
Table 2 Association of serum thyroid stimulating hormone with cognitive function test scoresa in AD patients
Variable Cognitive function test scores
MMSE MES
β(SE) P value 95 % CI for B β(SE) P value 95 % CI for B
TSH -0.20(0.34) 0.012 -1.52–0.19 -0.20 (1.09) 0.012 -4.97–0.63
aLinear regression models adjusted for age, sex, years of education and BMI
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normal control (P < 0.05), whereby the mean fT3 level of
the AD group was higher. Differences in MMSE and
MES scores among the three groups were statistically
significant. Lowest MMSE and MES scores were ob-
served in the AD groups (P < 0.05).
Pearson’s correlation analysis was performed to
evaluate the relationships among serum thyroid hor-
mone levels, age, education years and cognitive func-
tion test scores in all groups (data not shown). Serum
fT4 levels were inversely associated with education
years in the normal control (γ = -0.26, P < 0.05). No
significant correlations were evident among serum
thyroid hormone levels, age, body mass index, educa-
tion years and cognitive function test scores in MCI
patients. Serum fT3 level was inversely associated
with age in AD patients (γ = -0.21, P < 0.05). Similar
associations were found between serum TSH levels
and MMSE and MES scores in AD patients (γ = -0.21,
P < 0.05; γ = -0.21, P < 0.05, respectively). Associations
of serum TSH levels with cognitive function test
scores in AD patients are presented in Table 2.
Based on serum TSH, all patients were divided into
five groups. Compared with the fifth quintile, partici-
pants in the lowest and second lowest quintiles of TSH
presented odds ratio (OR) for AD of 2.78 (95 % confi-
dence interval [95% CI], 1.11–6.99) and 2.58 (95 % CI,
1.04–6.39), respectively. All analyses were adjusted for
age, sex, years of education and body mass index. The
same analyses on subjects with MCI revealed no signifi-
cant associations. A summary of logistic regression ana-
lyses is presented in Table 3.
Among the 295 recruited participants, 260 had nor-
mal thyroid function (20.8 % with MCI and 52.7 %
with AD). Hypothyroidism was diagnosed in 14 indi-
viduals (12.3 % with MCI and 57.1 % with AD), whileTable 3 Summary of logistic regression analysesa





aLinear regression models adjusted for age, sex, years of education and BMI
bFifth quintile as the reference9 had subclinical hypothyroidism (22.2 % with MCI
and 55.6 % with AD). There were 12 cases of
subclinical hyperthyroidism, including 6 MCI (50.0 %)
and 4 AD (33.3 %) patients. No diagnosis of clinical
hyperthyroidism was ascertained. Demographic
characteristics and distribution of different covariates
among the four groups (clinical hypothyroidism, sub-
clinical hypothyroidism, normal thyroid function and
subclinical hyperthroidism) are described in Table 4.
Compared with the normal thyroid function group, we
found no significant association between MCI and thy-
roid dysfunction after adjusting the model for covariates
of age, sex, education years and body mass index (OR,
0.72, 95 % CI, 0.12–4.27; OR, 1.06, 95 % CI, 0.14–8.00;
OR, 0.25, 95 % CI, 0.05–1.30, respectively) (Table 5).
Similarly, no association of thyroid dysfunction with AD
was observed in the multivariate adjusted model (OR,
1.33, 95 % CI, 0.37–4.79; OR, 1.27, 95 % CI, 0.24–6.99;
OR, 1.08, 95 % CI, 0.19–6.13) (Table 5).
Discussion
In the current cross-sectional study on elderly partici-
pants, we observed no significant association of cogni-
tive impairment with hypothyroidism and subclinical
hyperthyroidism after accounting for possible interac-
tions and confounding factors. Our findings are consist-
ent with those of previous studies reporting a lack of
association between thyroid dysfunction and cognitive
decline [10, 31–33]. However, it must be noted that the
earlier reports did not specifically focus on the associ-
ation of clinical and subclinical hypothyroidism with
MCI.
On the other hand, several studies have reported that
both higher and lower TSH levels within the reference
interval are associated with poor cognitive performance





Table 4 Demographic and clinical characteristics of participants with normal thyroid function and thyroid dysfunction
Characteristic Hypothyroidism Subclinical Hypothyroidism Normal Thyroid Function Subclinical Hyperthroidism P
value(n = 14) (n = 9) (n = 260) (n = 12)
Cognition, No. (%) 0.974
NC 4 (28.6 %) 2 (22.2 %) 69 (26.5 %) 2 (16.7 %)
MCI 2 (12.3 %) 2 (22.2 %) 54 (20.8 %) 6 (50.0 %)
AD 8 (57.1 %) 5 (55.6 %) 137(52.7 %) 4 (33.3 %)
Age, years (Mean ± SD) 65.9 ± 10.9 62.9 ± 11.7 63.7 ± 9.7 64.1 ± 6.5 0.855
Education, years (Mean ± SD) 11.6 ± 4.8 7.4 ± 3.6 9.2 ± 3.8 10.2 ± 3.3 0.078
Gender, No. (%) 0.401
Male 7 (50.0 %) 3 (33.3 %) 147 (56.5 %) 5 (41.7 %)
Female 7 (50.0 %) 6 (66.7 %) 113 (43.5 %) 7 (58.3 %)
BMI, kg/m2(Mean ± SD) 23.0 ± 3.2 23.3 ± 3.1 23.2 ± 3.2 23.3 ± 3.2 0.840
MMSE Score (Mean ± SD) 20.3 ± 6.7 17.6 ± 10.2 20.7 ± 7.6 23.3 ± 5.1 0.400
MES Score (Mean ± SD) 52.96 ± 23.3 41.4 ± 30.0 52.9 ± 27.1 59.1 ± 18.1 0.514
NC normal control, BMI body mass index
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studies [8, 11, 35] demonstrating increased risk of AD in
elderly persons with lower TSH levels. Further validation
of the role of TSH as a predictor of AD is warranted
with prospective studies using larger sample sizes.Table 5 Association of thyroid dysfunction with mild cognitive
































aMultivariate adjustment for age, sex, education years and body mass indexAlzheimer’s disease (AD) is one of the most common
causes of dementia in the elderly, affecting more than 24
million individuals worldwide [36]. By the end of 2011,
the elderly population over 60 years of age in China was
185 million, comprising 13.76 % of the overall popula-
tion. Aging and Alzheimer’s disease (AD) are serious
public health concerns and causes of social problems in
China. MCI, classically defined as a transitional state be-
tween normal cognition and dementia [37], is a pro-
dromal stage of clinical dementia defined by cognitive
decline greater than expected for normal aging but
preservation of activities of daily living. MCI occurs
in ~15 % of elderly patients [38], presenting a poten-
tial target group for early identification and interven-
tion of dementia.
While the biological pathways underlying the associ-
ation of low TSH with AD risk remain to be established,
proposed theories include both thyroxine-mediated
mechanisms and direct effects of TSH on amyloid-β. AD
pathology has been proposed to trigger a reduction in
secretion of thyroid releasing hormone (TRH), which
functions as a neurotransmitter. TRH is secreted not
only from hypothalamus but also other areas of the
brain, and its secretion may be decreased in the brain of
subjects at risk of cognitive decline [39]. Our data show-
ing that subjects with lower TSH are at higher risk of
AD support this theory.
Both clinical and subclinical thyroid dysfunction affect
cardiovascular risk [40–42]. In parallel, vascular risk factors
have been associated with increased risk for AD [43, 44].
The toxicity of thyroid hormone excess to brain is
exerted through direct effects on the processing of cerebral
amyloid-β proteins and/or local synthesis and release of
acetylcholine from neurons. Thyroid hormone has been
shown to regulate gene expression of amyloid-β protein
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hormone levels may therefore contribute to progression of
AD by directly increasing APP expression, and conse-
quently, amyloid-β peptide and protein levels. In parallel,
TRH depletion is associated with enhanced phosphoryl-
ation of tau protein [45]. Increased oxidative stress and
decreased antioxidant metabolites have been detected in
hyperthyroid patients [46], and exposure to thyroid hor-
mone reported to enhance neuronal death [47].
Our study has a number of significant weaknesses and
strengths. This was a cross-sectional analysis on individ-
uals enrolled from a hospital, preventing us from making
causal inferences. However, the current report is one of
the first to address the association of thyroid dysfunction
with cognitive impairment in the elderly Chinese popu-
lation, which was assessed using CMMSE and MES that
present reliable approaches for evaluation of cognitive
function in MCI.
Conclusion
Our results clearly demonstrate that hypothyroidism
and subclinical hyperthyroidism are not associated
with AD and MCI. The current findings need to be
further validated in a longitudinal study. This report
contributes to the growing body of evidence showing
that hypothyroidism is not associated with MCI.
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